Shares of Enzymotec Ltd. (NASDAQ:ENZY) have received an average broker rating score of 3.33 (Hold) from the three analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a sell recommendation and two have assigned a hold recommendation to the company.

Brokers have set a 1 year consensus price target of $10.30 for the company and are expecting that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also given Enzymotec an industry rank of 179 out of 265 based on the ratings given to related companies.

Several analysts have commented on ENZY shares. Wells Fargo & Company lifted their target price on shares of Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research note on Monday, October 30th. Jefferies Group LLC restated a “hold” rating and set a $11.50 target price on shares of Enzymotec in a report on Thursday, October 19th. Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a report on Saturday, August 12th.

Several institutional investors have recently modified their holdings of ENZY. Janus Henderson Group PLC acquired a new stake in shares of Enzymotec in the 2nd quarter valued at about $2,350,000. Osborn Williams & Donohoe LLC acquired a new stake in shares of Enzymotec in the 3rd quarter valued at about $137,000. JPMorgan Chase & Co. acquired a new stake in shares of Enzymotec in the 3rd quarter valued at about $107,000. Finally, State Street Corp raised its stake in shares of Enzymotec by 1.8% in the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 380 shares in the last quarter. Institutional investors and hedge funds own 26.59% of the company’s stock.

Shares of Enzymotec (NASDAQ:ENZY) traded up $0.03 during trading hours on Monday, reaching $11.85. 8,800 shares of the company were exchanged, compared to its average volume of 64,160. Enzymotec has a 1 year low of $5.40 and a 1 year high of $12.35.

ILLEGAL ACTIVITY WARNING: “Zacks: Enzymotec Ltd. (ENZY) Receives Consensus Rating of “Hold” from Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/20/zacks-enzymotec-ltd-enzy-receives-consensus-rating-of-hold-from-brokerages.html.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Get a free copy of the Zacks research report on Enzymotec (ENZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.